Agios (AGIO) CMO Sarah Gheuens Sells 30,000 Shares

What Happened
Sarah Gheuens, Chief Medical Officer of Agios Pharmaceuticals, sold 30,000 shares on August 4, 2026. The weighted-average sale price was $30.48 per share for total gross proceeds of approximately $914,400. The transaction is reported as a sale (S).

Key Details

• Transaction date: 2026-08-04; filing date: 2026-08-06 (reported two days after the trade).
• Price: weighted average $30.48; individual sale prices ranged from $30.25 to $30.88 (per filing).
• Shares owned after transaction: not specified in the provided excerpt of the Form 4.
• Notable footnotes: (1) Sale effected pursuant to a Rule 10b5-1 trading plan; (2) weighted-average price reported, seller can provide per-price breakdown on request.
• Timeliness: Filing appears timely (no late-filing indication in the provided data).

Context
This was an open-market sale executed under a pre-established 10b5-1 plan, which typically schedules trades in advance and can limit the inference that the trade reflects the insider’s current view of the company. Sales are common for liquidity or diversification reasons; purchases are generally given more weight when interpreting insider sentiment.